Clinical

Dataset Information

0

A double arm, prospective and exploratory phase II clinical study of Camrelizumab combined with or without bevacizumab / apatinib mesylate in the treatment of locally advanced rectal cancer


ABSTRACT: Interventions: control group:Camrelizumab;experimental group 1:Camrelizumab;experimental group:bevacizumab / apatinib Primary outcome(s): complete pathological response rate Study Design: Non randomized control

DISEASE(S): Colorectal Cancer

PROVIDER: 2759992 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2686078 | ecrin-mdr-crc
| 2690370 | ecrin-mdr-crc
2021-11-03 | GSE185783 | GEO
| 2679186 | ecrin-mdr-crc
| 2314620 | ecrin-mdr-crc
| 85219 | ecrin-mdr-crc
2019-05-15 | GSE129221 | GEO
| 2670828 | ecrin-mdr-crc
| 2716800 | ecrin-mdr-crc
| 2676687 | ecrin-mdr-crc